Breaks Categories: Stock Spotlights

MondayApr 03, 2023 3:22 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching potential. “Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (‘APIs’). DehydraTECH increases the effectiveness of and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include: speed up in delivery time; increased bioavailability; increased brain absorption; improved drug potency; and reduction in drug administration costs. Animal studies of DehydraTECH have demonstrated the ability to elevate the quantity of the drug delivered across…

Continue Reading

FridayMar 24, 2023 12:36 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected.…

Continue Reading

FridayMar 17, 2023 1:31 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing. No statistically significant reductions in catestatin concentrations were identified in the placebo group,” a recent article reads. “Given the growing demand for alternative anti-hypertensive…

Continue Reading

MondayMar 13, 2023 2:49 pm

CBDNewsBreaks – Prime Harvest Inc. Secures Reg A+ Qualification, Eyes New Heights of Opportunity

Prime Harvest, a technology focused, full-service cannabis company, recently announced that its Regulation A+ offering, which seeks to raise up to $42 million, had been qualified by the U.S. Securities and Exchange Commission (“SEC”). “The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s state-wide delivery capabilities, as well as general corporate purposes,” a recent article reads. “Dating back to the company’s change in corporate strategy in 2019, a move which saw Prime Harvest transition from its origins as…

Continue Reading

FridayMar 10, 2023 1:20 pm

CBDNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s. IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing drug candidate. In phase 1 studies,…

Continue Reading

WednesdayMar 08, 2023 3:17 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories

Lexaria (NASDAQ: LEXX) is a global innovator in drug delivery platforms. “The company’s patented DehydraTECH(TM) technology enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual and topical products. According to Lexaria, its technology ‘is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies that offer consumer supplements, prescription and non-prescription-based drugs and nicotine products,’” a recent article reads. “When analyzed in terms of numbers, the improvements are impressive. Having conducted both in vitro and in vivo studies, Lexaria…

Continue Reading

FridayFeb 24, 2023 3:56 pm

CBDNewsBreaks – Prime Harvest Inc. Delivering Excellence in Legal Access to Cannabis, Best-in-Class Experiences

Prime Harvest is a full-service cannabis company that focuses on licensing, acquisition, compliance management, and direct-to-consumer operations. The company aims to provide first-in-class cannabis experiences while enriching local stakeholders. “Social initiatives and philanthropy have always been a part of Prime Harvest Inc.’s mission. The company is a proud member of the Community Alliance Program (‘CAP’), which provides assistance for educational programs, veterans, urban farms, and the arts. In addition, the CAP advocates for safe access to cannabis medicine for individuals in need. Scientific research continues to validate therapeutic cannabis use for numerous conditions, including multiple sclerosis, anxiety, chronic neuropathic pain,…

Continue Reading

FridayFeb 17, 2023 12:58 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled Transdermal And/or Dermal Delivery of Lipophilic Active Agents. “The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (‘CBD’) and tetrahydrocannabinol (‘THC’), all established on the company’s patented DehydraTECH technology,” a recent article reads. “In Lexaria’s 2018 study, DehydraTECH-CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial…

Continue Reading

FridayFeb 10, 2023 1:24 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH(TM)-processed CBD compared to those of published comparators. “In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had been reached) with that of non-Lexaria, pharmaceutical-grade CBD formulations published in two studies – a 2017 clinical trial and a 2019 study,” a recent article reads. “The 2017 trial evidenced an average blood plasma CBD…

Continue Reading

ThursdayFeb 02, 2023 1:30 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology, which is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. “DehydraTECH increases effectiveness and improves how these ingredients enter the bloodstream. Benefits of DehydraTECH include: improved speed of onset, with effects felt in minutes; increased bioavailability, with more of the drug delivered into the bloodstream; increased brain absorption, with testing suggesting up to 10x improvement; and improved drug potency, with more of the ingested product made available in the bloodstream requiring lower dosages,” a recent article reads. “Animal studies…

Continue Reading